Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT06158841 · RECRUITING

Trial details

NCT number: NCT06158841
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2024-05-19
Primary completion: 2027-12-01
Enrollment: 380

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.